[{"id":"520d484b-1d72-40b4-bb03-724f2c206c70","acronym":"","url":"https://clinicaltrials.gov/study/NCT03844750","created_at":"2021-01-18T18:58:53.308Z","updated_at":"2025-02-25T15:26:02.208Z","phase":"Phase 2","brief_title":"Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases","source_id_and_acronym":"NCT03844750","lead_sponsor":"Chloe Atreya, MD, PhD","biomarkers":" PD-L1 • MLH1 • MSH6 • MSH2","pipe":"","alterations":" ","tags":["PD-L1 • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • vactosertib (TEW-7197)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 07/22/2019","start_date":" 07/22/2019","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-11"},{"id":"73399e14-1a22-4a4d-9341-b7370611d1e0","acronym":"MP-VAC-203","url":"https://clinicaltrials.gov/study/NCT03732274","created_at":"2021-01-17T17:24:28.913Z","updated_at":"2025-02-25T15:08:02.565Z","phase":"Phase 1/2","brief_title":"Phase 1b/2a, Open-label Study of Vactosertib in Combination with Durvalumab in Advanced NSCLC","source_id_and_acronym":"NCT03732274 - MP-VAC-203","lead_sponsor":"MedPacto, Inc.","biomarkers":" UGT1A1","pipe":" | ","alterations":" PD-L1 expression","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • vactosertib (TEW-7197)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 05/17/2024","primary_completion_date":" 05/17/2024","study_txt":" Completion: 12/23/2024","study_completion_date":" 12/23/2024","last_update_posted":"2024-12-09"},{"id":"51fadde5-112f-4f54-9c1a-1d98923a6851","acronym":"","url":"https://clinicaltrials.gov/study/NCT05436990","created_at":"2022-06-29T15:59:17.227Z","updated_at":"2024-07-02T16:36:08.129Z","phase":"Phase 2","brief_title":"Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor","source_id_and_acronym":"NCT05436990","lead_sponsor":"Yonsei University","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • vactosertib (TEW-7197)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2022-06-29"},{"id":"b737e733-8589-40bf-8cc3-cbbb31f0c7c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04515979","created_at":"2021-01-18T21:38:25.463Z","updated_at":"2024-07-02T16:36:23.994Z","phase":"Phase 2","brief_title":"Vactosertib in Combination With Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects","source_id_and_acronym":"NCT04515979","lead_sponsor":"MedPacto, Inc.","biomarkers":" EGFR • PD-L1 • BRAF • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • PD-L1 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • vactosertib (TEW-7197)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 12/17/2020","start_date":" 12/17/2020","primary_txt":" Primary completion: 08/01/2022","primary_completion_date":" 08/01/2022","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2021-09-24"},{"id":"864c94fc-7fa7-4d07-bb9c-f60c034481f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03698825","created_at":"2021-01-18T18:07:41.705Z","updated_at":"2024-07-02T16:36:33.073Z","phase":"Phase 1/2","brief_title":"TEW-7197 With Paclitaxel for the Treatment of Metastatic Gastric Cancer","source_id_and_acronym":"NCT03698825","lead_sponsor":"MedPacto, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • vactosertib (TEW-7197)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 08/15/2018","start_date":" 08/15/2018","primary_txt":" Primary completion: 12/20/2021","primary_completion_date":" 12/20/2021","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2021-03-19"}]